SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2024
Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Efficacy of biologic agents in patients with comorbid asthma and chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma.Advances in therapy · 2025Pooled it
- The efficacy and safety of biologics for patients with severe asthma: an umbrella review of systematic reviews and meta-analyses.Frontiers in medicine · 2025Pooled it
- Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial.Clinical pharmacology and therapeutics · 2026Trial
- Consistent adherence to biologic therapies is critical for improving outcomes in asthma.The journal of allergy and clinical immunology. Global · 2026Article
- An Eight-Century Evolution of Asthma Therapeutics in Western Countries: From Medieval Regimens to Anti-inflammatory Reliever Therapy and Precision Biologics.Advances in therapy · 2026Review
- Emerging Targeted Therapies in Asthma: From Upstream Epithelial Biology to Novel Biologic and Small-Molecule Strategies.Tuberculosis and respiratory diseases · 2026Review
- Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews.Pediatric pulmonology · 2026Review
- Review
- The therapeutic effects of dupilumab in asthma-chronic obstructive pulmonary disease overlap and pure asthma: a pilot study.Journal of thoracic disease · 2026Article
- Review
- Age-specific efficacy of biologics in severe asthma: a pediatric perspective.Frontiers in allergy · 2026Review
- From FEVJournal of asthma and allergy · 2026Review
- Tezepelumab: redefining TSLP blockade in severe asthma through mechanistic precision and translational pharmacology.Frontiers in pharmacology · 2026Review
- Feasibility of a 50% Dosing Interval Extension of Anti-IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study.Journal of asthma and allergy · 2026Article
- Screening and Preliminary Validation of Parthanatos-Related Key Genes in Asthma Using Transcriptomic and Machine Learning Approaches.Journal of inflammation research · 2026Article
- Understanding disease burden, challenges in current treatment strategies and call for action for management of severe asthma in Asia: a position statement from Asian respiratory experts.Frontiers in allergy · 2026Review
- Precision Medicine for Asthma: Tailored to its Severity and Endotype/Phenotype.Allergy, asthma & immunology research · 2026Review
- Adherence to Biologic Therapies is Associated with Improved Clinical Outcomes and Reduced Healthcare Resource Utilization in Patients with Severe Asthma in Japan.Journal of asthma and allergy · 2026Article
- Biologic Underutilization and Healthcare Burden in US Patients with Type 2 Severe Asthma.Journal of asthma and allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSix biologic agents are now approved for patients with severe asthma. This meta-analysis aimed to assess the efficacy and safety of licensed biologic agents in patients with severe asthma, including the recently approved tezepelumab.
methodsWe searched MEDLINE, Embase and CENTRAL to identify randomised controlled trials involving licensed biologics until 31 January 2023. We used random-effects meta-analysis models for efficacy, including subgroup analyses by individual agents and markers of T2-high inflammation (blood eosinophils and fractional exhaled nitric oxide), and assessed safety.
results48 studies with 16 350 patients were included in the meta-analysis. Biologics were associated with a 44% reduction in the annualised rate of asthma exacerbations (rate ratio 0.56, 95% CI 0.51-0.62) and 60% reduction of hospitalisations (rate ratio 0.40, 95% CI 0.27-0.60), a mean increase in the forced expiratory volume in 1 s of 0.11 L (95% CI 0.09-0.14), a reduction in asthma control questionnaire by 0.34 points (95% CI -0.46--0.23) and an increase in asthma quality of life questionnaire by 0.38 points (95% CI 0.26-0.49). There was heterogeneity between different classes of biologics in certain outcomes, with overall greater efficacy in patients with T2 inflammation. Overall, biologics exhibited a favourable safety profile.
conclusionsThis comprehensive meta-analysis demonstrated that licensed asthma biologics reduce exacerbations and hospitalisations, improve lung function, asthma control and quality of life, and limit the use of systemic corticosteroids, with a favourable safety profile. These effects are more prominent in patients with evidence of T2 inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.